Non-Alcoholic Fatty Liver Disease Clinical Trials

Find Non-Alcoholic Fatty Liver Disease Clinical Trials Near You

Impacts of Peanut Intake on Hepatic Markers and Gut Microbiota in Adults With MASLD

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The aim of this randomized interventional trial is to understand the effects of peanut consumption on patients with metabolic associated fatty liver. The main goal is to investigate if patients who consume peanuts have improved liver marker tests as well as metabolic profile. We will also investigate how peanuts alter the gut microbes and liver fat content in patients with metabolic associated fatty liver. * Participants will be randomized into intervention (peanut consumption for 12 weeks) and control (regular diet) arm. * Stool sample and blood (for biomarkers) collection across both arms at baseline and post-intervention * Daily log to be completed for tracking peanut consumption * 2-day Dietary recall at baseline, during Week 6 and Week 12 * Poat intervention Fibro scans for participants with baseline scans available

Eligibility
Participation Requirements
Sex: All
Minimum Age: 30
Maximum Age: 70
Healthy Volunteers: f
View:

• 30-70 years

• do not consume peanut/peanut butter/treenut/seeds \> /week

• at least one encounter-related (stage F0/F1) MASLD diagnosis (K76.0)

• Able to understand, speak, and read English

• Mentally competent to consent

Locations
United States
Michigan
Henry Ford Health System
RECRUITING
Detroit
Contact Information
Primary
Menghua Tao, PhD
mtao1@hfhs.org
313-590-9408
Time Frame
Start Date: 2026-06-09
Estimated Completion Date: 2028-06-09
Participants
Target number of participants: 125
Treatments
Experimental: Peanut
MASLD patients will consume 50 gm of peanut daily for 12 weeks
No_intervention: Control
Regular diet
Related Therapeutic Areas
Sponsors
Leads: Henry Ford Health System

This content was sourced from clinicaltrials.gov